Loading...

ADVM ADVERUM BIOTECHNOLOGIES INC Operational Disruptions 8-K Filing

DVRM

DVM

ADVERUM BIOTECHNOLOGIES INC

(ADVM)

2024 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Financial Restatement

Positive Trial Results

Financial Results

Financial Results

Corporate Presentation and ...

Annual Meeting Results

Appointment and Resignation...

Financial Results Announcement

Reverse Stock Split

Financial Results Announcement

Corporate Presentation Upda...

Settlement Agreement for St...

Securities Purchase Agreement

Delisting Notice

Appointment of Dr. Nicholson

Financial Results Announcement

Appointment of Director

Earnings Reports

Appointment of CFO

Compliance regained with Na...

Annual Meeting of Stockholders

Management Change

Sales Agreement with Cowen ...

Earnings Reports

External Links:

Adverum Biotechnologies, Inc. updated its corporate presentation and announced efficacy and safety results from the LUNA Phase 2 trial of Ixoberogene soroparvovec (Ixo-vec) in patients with wet age-related macular degeneration (AMD).

AI Assistant

ADVERUM BIOTECHNOLOGIES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.